Sethi Kapil
Medical College of Georgia, Augusta, Georgia, USA.
Mov Disord. 2008;23 Suppl 3:S521-33. doi: 10.1002/mds.22049.
Levodopa has been the mainstay of symptomatic therapy for Parkinson Disease (PD) for 40 years providing benefit to virtually all patients. Levodopa therapy results in improved activities of daily living, enhanced quality of life, and improved mortality. However, the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesia. In addition, levodopa therapy has further limitations. It has little or no effect on certain motor features (e.g. gait and balance dysfunction) and a non-motor symptom complex (autonomic dysfunction, pain syndromes, sleep disorders, mood disturbances, dementia). Further, multiple case reports illustrate the potential of levodopa and other dopaminergic agents to cause or reveal a series of impulse control disorders. This review highlights the levodopa unresponsive symptoms in PD.
左旋多巴40年来一直是帕金森病(PD)症状性治疗的主要手段,几乎对所有患者都有益处。左旋多巴治疗可改善日常生活活动能力、提高生活质量并降低死亡率。然而,长期使用左旋多巴会导致运动波动和异动症的发生。此外,左旋多巴治疗还有其他局限性。它对某些运动特征(如步态和平衡功能障碍)以及非运动症状复合体(自主神经功能障碍、疼痛综合征、睡眠障碍、情绪障碍、痴呆)几乎没有影响。此外,多个病例报告表明左旋多巴和其他多巴胺能药物有引发或揭示一系列冲动控制障碍的可能性。本综述重点介绍了帕金森病中对左旋多巴无反应的症状。